GHIF Webinar: Raydiant Oximetry
Monday, June 2, 2025
GHIF II is now live and actively fundraising to ensure continued support to Raydiant.
GHIF II is now live and actively fundraising to ensure continued support to Raydiant.
Global Health Impact Fund (GHIF) is a clinician-founded healthcare venture capital firm based in Silicon Valley, with a proven track record of identifying and supporting transformative healthtech startups.
Our inaugural fund, GHIF I — launched in 2019 and fully subscribed at $10M — has achieved two successful exits from 10 investments:
Somnoware, acquired by ResMed in 2023 (3.3x return)
UBERDOC, acquired by ROV Investment Partners in 2025
We’re now raising GHIF II, targeting $50M, with a first close at $25M. Notably, 40% of GHIF I Limited Partners have already reinvested — a strong vote of confidence in our strategy and performance.
A key focus of GHIF II is Raydiant Oximetry, a clinical-stage medical device company advancing maternal and fetal health. GHIF has been a committed investor since Raydiant’s seed round in 2019, supporting its FDA approval, major grants from the Gates Foundation and NIH, and a recent joint development initiative with GE HealthCare.
GHIF II plans to participate in Raydiant’s Series B round, with an anticipated exit in 2026 offering strong return potential.
